SPH43350

SPH43350 is an investigational small molecule inhibitor of the KRAS (Kirsten rat sarcoma virus) protein, developed by Shanghai Pharmaceuticals Holding Co., Ltd. KRAS is a member of the RAS family of small GTPases that play a critical role in regulating cell growth, differentiation, and survival. Mutations in KRAS, particularly at codons 12, 13, or 61, are among the most common drivers in human cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic ductal adenocarcinoma. SPH43350 is designed to selectively inhibit the activity of mutated KRAS, thereby suppressing the downstream MAPK/ERK and PI3K/AKT signaling pathways that promote oncogenesis. As of early 2024, SPH43350 is in the Investigational New Drug (IND) stage of development for the treatment of solid tumors.